Use this link to cite:
http://hdl.handle.net/2183/37188 Rationale and design of the ESC Heart Failure III Registry – Implementation and discovery
Loading...
Identifiers
Publication date
Authors
Lund, Lars H.
Laroche, Cécile
García-Pinilla, José Manuel
Bennis, Ahmed
Vataman, Eleonora
Polovina, Marija
Radovanovic, Slavica
Apostolovic, Svetlana R.
Asanin, Milika
Advisors
Other responsabilities
Journal Title
Bibliographic citation
Lund LH, Crespo-Leiro MG, Laroche C, Garcia-Pinilla JM, Bennis A, Vataman EB, Polovina M, Radovanovic S, Apostolovic SR, Ašanin M, Gackowski A, Kaplon-Cieslicka A, Cabac-Pogorevici I, Anker SD, Chioncel O, Coats AJS, Filippatos G, Lainscak M, Mcdonagh T, Mebazaa A, Metra M, Piepoli M, Rosano GM, Ruschitzka F, Savarese G, Seferović PM, Iung B, Popescu BA, Maggioni AP; ESC EORP HF III National Leaders and Investigators. Rationale and design of the ESC Heart Failure III Registry - Implementation and discovery. Eur J Heart Fail. 2023 Dec;25(12):2316-2330.
Type of academic work
Academic degree
Abstract
[Abstract]
Aims: Heart failure outcomes remain poor despite advances in therapy. The European Society of Cardiology Heart Failure III Registry (ESC HF III Registry) aims to characterize HF clinical features and outcomes and to assess implementation of guideline-recommended therapy in Europe and other ESC affiliated countries.
Methods: Between 1 November 2018 and 31 December 2020, 10 162 patients with chronic or acute/worsening HF with reduced, mildly reduced, or preserved ejection fraction were enrolled from 220 centres in 41 European or ESC affiliated countries. The ESC HF III Registry collected data on baseline characteristics (hospital or clinic presentation), hospital course, diagnostic and therapeutic decisions in hospital and at the clinic visit; and on outcomes at 12-month follow-up. These data include demographics, medical history, physical examination, biomarkers and imaging, quality of life, treatments, and interventions - including drug doses and reasons for non-use, and cause-specific outcomes.
Conclusion: The ESC HF III Registry will provide comprehensive and unique insight into contemporary HF characteristics, treatment implementation, and outcomes, and may impact implementation strategies, clinical discovery, trial design, and public policy.
Description
Editor version
Rights
Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC-BY-NC-ND 4.0)
Collections
Except where otherwise noted, this item's license is described as Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC-BY-NC-ND 4.0)